SPDR S&P Biotech ETF (NYSEARCA:XBI) Shares Sold by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. lowered its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 5.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 254,583 shares of the exchange traded fund’s stock after selling 14,376 shares during the quarter. Raymond James Financial Services Advisors Inc. owned approximately 0.33% of SPDR S&P Biotech ETF worth $22,732,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in SPDR S&P Biotech ETF by 179.1% during the 1st quarter. JPMorgan Chase & Co. now owns 7,534,471 shares of the exchange traded fund’s stock valued at $574,202,000 after acquiring an additional 4,835,071 shares in the last quarter. Jane Street Group LLC grew its holdings in shares of SPDR S&P Biotech ETF by 111.4% in the 2nd quarter. Jane Street Group LLC now owns 172,730 shares of the exchange traded fund’s stock worth $12,829,000 after acquiring an additional 1,682,382 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of SPDR S&P Biotech ETF in the 3rd quarter worth $102,900,000. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of SPDR S&P Biotech ETF by 103.3% in the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,771,000 shares of the exchange traded fund’s stock worth $129,318,000 after acquiring an additional 900,000 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of SPDR S&P Biotech ETF in the 1st quarter worth $34,666,000.

SPDR S&P Biotech ETF Stock Down 0.0 %

Shares of NYSEARCA XBI opened at $94.89 on Friday. SPDR S&P Biotech ETF has a 52-week low of $63.80 and a 52-week high of $103.52. The stock has a market capitalization of $7.28 billion, a price-to-earnings ratio of 11.47 and a beta of 0.97. The stock’s fifty day simple moving average is $93.43 and its 200 day simple moving average is $82.66.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.